Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Abstract KRAS mutations represent the most common driver genetic alterations in multiple malignant tumors, particularly exerting well-defined oncogenic driver roles in non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. The recent success of KRAS G12C mutation-specif...
שמור ב:
| Principais autores: | , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer
2025-10-01
|
| סדרה: | Discover Oncology |
| נושאים: | |
| גישה מקוונת: | https://doi.org/10.1007/s12672-025-03569-x |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
